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Abstract
The analgesic effects of cannabinoids are well documented, but these are often limited by
psychoactive side-effects. Recent studies indicate that the endocannabinoid system is dynamic and
altered under different pathological conditions, including pain states. Changes in this receptor
system include altered expression of receptors, differential synthetic pathways for
endocannabinoids are expressed by various cell types, multiple pathways of catabolism and the
generation of biologically active metabolites, which may be engaged under different conditions. This
review discusses the evidence that pain states alter the endocannabinoid receptor system at key
sites involved in pain processing and how these changes may inform the development of
cannabinoid-based analgesics.
Receptor targets for the endocannabinoids and 
cannabinoids
The cannabis sativa plant contains 60 or more bioactive
phytocannabinoid compounds including Δ9-THC which
is the major psychoactive component [1]. A wide variety
of synthetic cannabinoids have been produced which
interact with cannabinoid receptors, two of which (CB1
and CB2) have been cloned. Both of these are inhibitory,
Gi protein-coupled receptors that reduce the formation of
cyclic AMP [2]. CB1 receptor activation also inhibits N-, L-
, and P/Q-type Ca2+ channels and activates K+ channels
and MAP kinases [for review see [3]]. CB1 receptors are
present pre-synaptically on axons and terminals of neu-
rones, with little or no expression on dendrites or soma
[4] and, therefore, are ideally located for the modulation
of synaptic activity. Thus, CB1 receptor activation inhibits
neurotransmitter release and neuronal excitability. CB2
receptors couple to similar signal transduction mecha-
nisms to CB1 receptors in terms of their actions on adeny-
lyl cyclase and MAP kinases, but do not share the same
interactions with ion channels as CB1 receptors [for review
see [3]].
A third G protein-coupled receptor, GPR55, binds a
number of cannabinoid ligands and, therefore, has been
proposed to be a member of the cannabinoid receptor
family [[5-8], for review see [9]], although the balance of
evidence is not supportive of this classification.
TRPV1 receptors are non-selective ion channels whose
location in sensory neurons allows them to gate responses
to painful stimuli such as high temperature and low pH
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[for review see [10]]. TRPV1 are activated by the arche-
typal endocannabinoid anandamide (AEA), albeit at
higher concentrations than those which stimulate CB
receptors. AEA has recently been shown to excite C-fibres
and produce nociceptive behaviour via the activation of
TRPV1 [11]. Under inflammatory conditions, such as in
the presence of bradykinin or prostaglandins, the sensitiv-
ity of TRPV1 to anandamide is increased [12]. Thus,
TRPV1 could be considered to be cannabinoid-sensitive
ion channel receptor. Other members of the TRP channel
family (e.g. TRPA1) also respond to some synthetic can-
nabinoids (see below). The CB1-independent actions of
endocannabinoids at other ion channels, including potas-
sium channels and voltage-gated calcium channels have
been previously reviewed [13,14]. CB receptor and G pro-
tein-independent blockade of the background potassium
channels TASK-1 and TASK-3 by AEA has been reported
[15], which would be expected to result in depolarisation
of sensory nerves and possible functional enhancement.
Conversely, Kim et al. [16] reported that AEA inhibited
tetrodotoxin-sensitive and tetrodotoxin-resistant sodium
channels in primary sensory nerves. Since this effect was
unaltered by either CB1 or CB2 receptor antagonists, or
capsazepine, a direct action on these channels may medi-
ate this inhibition. AEA has also been reported to directly
inhibit the function of alpha4beta2 nicotinic acetylcho-
line receptors, independent of CB1 receptors [17]. The
contribution of these CB1-independent actions of the
endocannabinoids to their analgesic effects is yet to be
fully explored. In this context, however, 5-HT3 receptors
have been implicated in the CB1 receptor-independent
analgesic effects of AEA [18].
There is increasing evidence for cannabinoid receptor-
independent effects of cannabinoids mediated through
the peroxisome proliferator activator receptor (PPAR)
family of nuclear receptors [19-23]. Three major isoforms
(α, β and γ-) of this ligand-dependent transcription factor
have been identified, with their roles in the regulation of
lipid metabolism well characterised and studied. Recent
studies have demonstrated the involvement of PPAR-α
and γ in a variety of additional physiological processes,
including inflammation and pain [22,24-28].
The CB1 receptor is expressed in neuronal tissue, both cen-
trally and peripherally, as well as in other peripheral
organs. CB1 receptors are present at lower densities in the
heart, lung, testis, ovary, bone marrow, thymus, uterus
and immune cells [29]. The CB1 receptor is the most abun-
dant G protein-coupled receptor in the brain [30], with
particularly high levels of expression in the striatum, cere-
bellum, basal ganglia, cerebral cortex and hippocampus
[30,31]. The widespread distribution of the CB1 receptor is
consistent with the multiplicity of effects of cannabinoid
agonists, including hypomotility, increased food intake,
disruption of short term memory consolidation, antinoc-
iception, deficits of executive function, anxiety/anxiolysis
and psychotropic effects. CB1 receptor density is moderate
to high in regions involved in pain transmission and
modulation, such as dorsal root ganglia (DRG), spinal
cord, thalamus, periaqueductal grey (PAG), amygdala and
rostroventromedial medulla [32]. The effects of cannabi-
noid agonists on brain function have been investigated
with functional magnetic resonance imaging. Systemic
administration of a non-selective CB1/CB2  agonist
increased regional cerebral blood flow, an indirect index
of brain activity, in cortical regions, the hippocampus,
PAG, nucleus accumbens and striatum [33]. Thus, the
brain regions activated by the cannabinoid ligand corre-
spond well to those regions identified by autoradio-
graphic approaches to express moderate to high levels of
CB1 receptors.
CB2 receptors are mainly expressed at high densities in
immune tissues, including macrophages, mast cells, and
the spleen. Nevertheless, a putative role of the CB2 recep-
tor in the nervous system is becoming apparent. Although
early studies failed to identify CB2 receptors in the central
nervous system, recent work has reported the presence of
CB2 mRNA in the spinal cord of control rats [34] and CB2
receptor protein in brain tissue [35,36]. The functional
role of CB2 receptors in the CNS is unclear. A functional
imaging study demonstrated that CB2 receptor antago-
nism did not alter brain activation evoked by systemic
administration of a non-selective cannabinoid agonist
[33]. These data suggest that CB2-mediated cannabinoid-
induced changes in brain activity are minor under control
conditions.
Cannabinoid receptor-mediated analgesia
The analgesic effects produced by activation of CB1 recep-
tors have been well described and extensively reviewed
[for reviews see [37-39]]. Activation of CB1 receptors in
the spinal cord [40-42] and in the periphery [43] attenu-
ates nociceptive responses of dorsal horn neurones in
naïve rats. Supra-spinal CB1 receptors, in a number of dis-
crete brain regions, make an important contribution to
the antinociceptive effects of cannabinoids in models of
acute/tonic pain [44-49]. The broad distribution of CB1
receptors in the brain underpins both their therapeutic
effects, such as analgesia, as well as their side-effects. To
avoid these psychoactive side-effects, the analgesic poten-
tial of selective activation of peripheral and spinal CB1
receptors has been studied. Anti-nociceptive effects of a
CB1 receptor agonist were substantially reduced in mice
with CB1 receptor gene deletion in the peripheral nocice-
ptors [50]. Thus, it appears that CB1 receptor agonists
which do not cross the blood brain barrier and, thereby,
selectively activate peripheral CB1 receptors, may provide
a promising analgesic strategy. This concept is supportedMolecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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by earlier work demonstrating that hindpaw injection of
CB1 receptor agonists produces antinociceptive effects in
models of inflammatory and chronic pain [42,43,51-55].
Although in most of these studies the effects of cannabi-
noid agonists were blocked by CB1 receptor antagonism,
it is important to note that the peripheral anti-hyperalge-
sic effects of the cannabinoid agonists ACEA and WIN
55,212-2 were mediated via actions at the TRPA1 ion
channel expressed by primary afferent fibres [56].
A number of studies have demonstrated analgesic effects
of CB2 receptor agonists in models of acute and chronic
pain [reviewed elsewhere by [57,58]]. Administration of
CB2 agonists systemically [59-61] or locally into the hind-
paw [60,62] attenuates nociceptive responses in naïve
rats. CB2 receptors are present in the skin and their activa-
tion is reported to release endorphins from keratinocytes,
acting via μ opioid receptors to produce analgesia [63].
There is little evidence that spinal [64] or supra-spinal
[65] CB2  receptors modulate nociceptive responses in
naive rats, despite the reported expression of supraspinal
CB2 receptors (see earlier). There is, however, evidence for
a novel functional role of CB2 receptors in the spinal cord
[64,66,67] and thalamus [65] of neuropathic rats. CB2
knockout mice exhibit exacerbated neuropathic pain
behaviour, including mirror image pain and enhanced
microglia and astrocyte activation, suggesting that up-reg-
ulation of CB2 receptors in the spinal cord in models of
neuropathic pain plays an important role in regulating
neuropathic pain behaviour [68]. Indeed, chronic treat-
ment with GW405833, a CB2 receptor agonist was able to
inhibit activation of microglia and astrocytes and attenu-
ate mechanical allodynia in neuropathic rats in vivo [69].
Furthermore, the robust inhibitory effects of CB2 receptor
activation on neuropathic pain behaviour have been
shown to be interferon-γ-dependent [70]. Collectively,
there is broad base of evidence supporting a major role of
spinal CB2 receptors in the modulation of neuropathic
pain responses. Importantly, CB2 receptor selective ago-
nists have been reported to be devoid of CNS-mediated
side effects [71].
Endocannabinoids
At the present time, five endogenous cannabinoid recep-
tor ligands (endocannabinoids) have been described, of
which anandamide (N-arachidonyl ethanolamine, AEA)
was the first to be identified [72]. Since then, 2-arachido-
noyl glycerol [2-AG; [73]], noladin ether [74], virod-
hamine [75] and N-arachidonoyl dopamine [NADA;
[76]] have been identified. The structurally-related, N-
acylethanolamines (NAEs) N-oleoyl ethanolamine (OEA)
and N-palmitoyl ethanolamine (PEA) are also widely dis-
tributed in the CNS and periphery, but their classification
as endocannabinoids is debatable, given their lack of
affinity for CB1 and CB2 receptors. They are, however,
PPAR ligands [77,78].
Endocannabinoids are widely believed to be synthesised
on demand (i.e. not stored in any cellular compartment
awaiting release) and their actions are rapidly terminated
by being taken up into cells where they are subject to enzy-
matic hydrolysis. The anti-nociceptive effects of exoge-
nously administered endocannabinoids have been well
described, AEA has anti-nociceptive effects in behavioural
models of acute and chronic pain [for review see [37]].
Similarly, 2-AG reduces pain behaviour in the tail-flick
[73] and formalin tests [79].
Endocannabinoid synthesis
Several different pathways are suggested to contribute to
the synthesis of the NAEs, AEA, OEA and PEA from their
corresponding  N-acyl phosphatidyl ethanolamine
(NAPE) precursor. The most widely studied pathway to
date involves NAPE-phospholipase D (PLD), which gen-
erates AEA, OEA or PEA from their precursor, N-arachido-
noyl PE (NArPE), N-oleoyl PE or N-palmitoyl PE,
respectively (Figure 1) [for review see [80]]. Regionally
heterogeneous expression of NAPE-PLD in the mouse
brain has been reported [81]. Targeted disruption of
NAPE-PLD in mice produces a significant reduction in the
brain levels of longer chain NAEs, specifically saturated N-
acyl chains with 20 or more carbon atoms [82]. By con-
trast, levels of longer chain polyunsaturated NAEs, includ-
ing AEA (C20:4) and C22:6 were unaltered in knock-out
mice, compared to NAPE-PLD+/+ mice [82]. Thus, NAPE-
PLD may not make a substantial contribution to the syn-
thesis of AEA in the brain under control conditions,
although this does not preclude an involvement of NAPE-
PLD in the synthesis of AEA in discrete brain regions or in
the elevated levels of AEA observed following noxious
stimulation (see below).
Two alternative pathways involving phospholipase-C
(PLC)-PTPN22 [83] and αβ hydrolase (αβH4)-GDE1 [81]
are able to generate NAEs, including AEA, OEA and PEA
(Figure 1). The functional relevance of these multiple
pathways is yet to be determined, but they may subserve
differential synthesis of NAEs that might be dependent on
the tissue in question. In vitro studies have suggested
cross-talk between the PLC-PTPN22 pathway and the
NAPE-PLD pathway in the generation of AEA [83].
Lipopolysaccharide (LPS) treatment of RAW264.7 cells
has been shown to increase levels of AEA, despite reducing
NAPE-PLD mRNA. siRNA knockdown of NAPE-PLD in
RAW264.7 cells did not alter basal levels of AEA, but
increased LPS-stimulated AEA generation, compared to
mock-transfected cells [83], providing further support for
cross-talk between these synthetic pathways. These in vitro
data suggest that, in situations where NAPE-PLD genera-
tion of AEA is compromised, the PLC-PTPN22 pathway
may have a compensatory role in maintaining levels of
AEA. Given the lack of effect of the targeted disruption of
NAPE-PLD on levels of AEA in the mouse brain, it is feasi-Molecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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ble that PLC-PTPN22 synthesis of AEA may occur in the
NAPE-PLD knockout. The potential role of the PLC-
PTPN22 pathway in the synthesis of other NAEs including
OEA and PEA remains to be determined.
Recent work has shown that NAPE-PLD independent bio-
synthesis of NAEs such as AEA, OEA and PEA, occurs via a
αβH4-GDE1 pathway in mouse brain and testes [81].
αβH4 is a B-type NAPE lipase capable of removing both
O-acyl chains from NAPE to yield glycerophosphoNAE
(GpNAE) [82]. GDE1, an acyl chain specific phosphodi-
esterase, then converts GpNAE to NAE [81]. Blockade of
this phosphodiesterase activity by EDTA increased levels
of long chain polyunsaturated (C20:4, GpAEA; C22:6,
GpDHEA) GpNAEs, as well as shorter chain saturated and
monounsaturated (C16:0, GpPEA; C18:1, GpOEA)
GpNAEs, with no effects on long chain saturated (C20:0)
species detected [81]. Further investigation is essential for
the understanding of the contribution of these additional
synthetic pathways to the maintenance of functional lev-
els of endocannabinoids under control conditions, as well
as under different pathological conditions such as chronic
pain states which are associated with elevated levels of
endocannabinoids.
In contrast to the NAE group of endocannabinoids, the
biosynthetic pathways of the acyl glycerols have been less
widely studied. Diacylglycerol (DAG), the immediate pre-
cursor of 2-AG, is produced from hydrolysis of arachido-
nate-containing membrane phosphoinositides (PI) or
phosphatidic acid (PA) depending on the cell type [for
review see; [84]]. Many synthetic pathways for 2-AG
upstream of DAG have been proposed in various cell
types, which are dependent on phospholipase Cβ (PLCβ)
[85]. Two DAG lipases (DAGLα and DAGLβ) catalyse the
hydrolysis of DAG to 2-AG [86]. 2-AG synthesis has also
been proposed to occur through a phospholipase A1
(PLA1) and phospholipase C (PLC) complementary path-
way [87]. DAGLα is located postsynaptically [88] support-
ing the role of 2-AG as a retrograde messenger [85].
Although DAGL has long been identified and well charac-
terised, its role in modulation of nociceptive processing is
only just starting to be clarified. Indeed, DAGLα mRNA is
present in the superficial dorsal horn neurones of the spi-
nal cord [89], a region that plays a key role in the process-
ing of nociceptive inputs.
Endocannabinoids and pain processing
AEA and 2-AG are present in key regions involved in the
detection, relay and integration of nociceptive inputs,
including the skin, DRG, spinal cord, PAG and rostral ven-
tromedial medulla. Converging evidence supports a role
of endocannabinoids in the tonic inhibition of pain
responses and the setting of nociceptive thresholds.
Indeed, spinal administration of selective CB1 receptor
antagonists increased evoked-firing of dorsal horn neu-
rones and thermal hyperalgesia [90]. Furthermore, levels
of endocannabinoids are altered under pathological con-
ditions such as inflammation and neuropathic pain
(Table 1). We have demonstrated a significant reduction
in levels of AEA and PEA in the hindpaw of rats with car-
rageenan-induced hindpaw inflammation [26]. Similarly,
levels of AEA, 2-AG and PEA were decreased in the hind-
paw following intraplantar injection of formalin [91]. By
contrast, Beaulieu et al., [92] reported no significant alter-
Proposed biosynthetic pathways for the generation of AEA  from its arachidonoyl containing NAPE (NArPE) precursor Figure 1
Proposed biosynthetic pathways for the generation 
of AEA from its arachidonoyl containing NAPE 
(NArPE) precursor. NAPEs are formed from phosphatidyl 
choline and phosphatidyl ethanolamine membrane precur-
sors by an as yet uncharacterised N-acyl transferase enzyme. 
The most widely accepted route of AEA biosynthesis is via 
NAPE-PLD [142,143]. This enzyme is also responsible for the 
generation of other NAEs including OEA and PEA from their 
corresponding NAPE precursor. The serine hydrolase αβh4 
can generate lysoNAPE and glycerophospho-N-acyl eth-
anolamine (GpNAE), including glycerophospho-N-arachido-
noyl ethanolamine (GpAEA), glycerophospho-N-oleoyl 
ethanolamine (GpOEA) and glycerophospho-N-palmitoyl 
ethanolamine (GpPEA) intermediates that are subsequently 
hydrolysed by a metal dependant phosphodiesterase to pro-
duce AEA, OEA and PEA, respectively. In mouse brain, this 
enzyme has been identified as GDE1 [144]. LPS induced syn-
thesis of AEA involves the generation of phosphorylated AEA 
(pAEA) via PLC which is then converted to AEA by phos-
phatases. In mouse brain, this phosphatase has been identi-
fied as PTPN22 [83]. Whether this third pathway contributes 
to the synthesis of other NAEs such as OEA and PEA 
remains to be determined.Molecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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ation in levels of AEA, 2-AG and PEA in the hindpaw of
formalin-treated rats. In addition to altering levels of
endocannabinoids at the site of injury, noxious stimula-
tion such as formalin-evoked hindpaw inflammation
increases levels of endocannabinoids at other targets in
the nociceptive pathway, such as the periaqueductal grey,
indicating a role for endocannabinoids in descending
control of pain processing [93]. Recent evidence suggests
that substance P underlies the 2-AG mediated disinhibi-
tion of the descending inhibitory control pathway [94].
Levels of endocannabinoids and NAEs are altered in dif-
ferent pain states, which may reflect altered synthesis or
catabolism. Levels of endocannabinoids are increased in
the spinal cord [91] and dorsal root ganglia (DRG) [95]
following peripheral nerve injury, a model of neuropathic
pain. We have shown that levels of AEA are increased,
whereas levels of PEA are decreased, in the spinal cord
[96] in a model of neuropathic pain. These data suggest
that there is differential synthesis, or catabolism, of AEA
and PEA in the spinal cord of neuropathic rats. Neuro-
pathic pain states are associated with activation of glial
cells, which contributes to the spinal sensitization and the
associated aberrant pain responses [for review see [97]].
As discussed earlier, there is evidence that the biosynthetic
pathways responsible for EC synthesis are cell type-
dependant. Activated microglia synthesize and metabo-
lize endocannabinoids [98-100] and, therefore, their pres-
ence in the spinal cord in models of neuropathic pain is
likely to influence the local availability of endocannabi-
noids under these conditions.
Table 1: A summary of the changes in levels of endocannabinoid and related compounds in models of inflammatory and neuropathic 
pain.
Model Tissue AEA 2-AG PEA OEA Reference
Inflammatory Pain
Formalin Rat Hindpaw skin ⇔⇔ -- [92]
Rat Hindpaw skin ⇔⇓ ⇔ - [91]
Mouse Hindpaw Skin ⇓⇓ ⇓ - [91]
Carrageenan Rat Hindpaw skin ⇓⇓ ⇓ ⇔ [26]
Neuropathic Pain
Spinal Nerve Ligation Rat L5 DRG ⇑ (day14) ⇑ (day 14) - - [95]
Rat L4 DRG ⇔ (day 14) ⇔ (day 14) - - [95]
Rat Lumbar Spinal Cord ⇑ (day 14) ⇑ (day 14) ⇓ (day 14) ⇔ (day 14) [96]
Rat Brain (Thalamus) ⇔ (day 14) ⇔ (day 14) ⇔ (day 14) ⇔ (day 14) [65]
Chronic Constriction 
Injury
Rat Lumbar Spinal Cord ⇑
(days 3 & 7)
⇑
(days 3 & 7)
⇑ (day 3)
⇔ (day 7)
- [139]
Rat Brain
(PAG)
⇑
(days 3 & 7)
⇑
(days 3 & 7)
⇔
(days 3 & 7)
- [139]
Rat Brain (RVM) ⇔ (day 3)
⇑ (day 7)
⇔ (day 3)
⇑ (day 7)
⇔
(days 3 & 7)
- [139]
Rat Brain
(DR)
⇔ (day 3)
⇑ (day 7)
⇔
(days 3 & 7)
⇔
(days 3 & 7)
- [139]
Rat Brain ⇔ (day 14) ⇔ (day 14) - - [133]
Rat Spinal cord ⇔ (day 14) ⇔ (day 14) - - [133]
⇔ = no change, ⇓ = decrease, ⇑ = increase, - = not measured. DRG = dorsal root ganglia, ECB, AEA = anandamide, 2-AG = 2-arachidonyl glycerol, 
PEA = palmitoyl ethanolamide, OEA = oleoyl ethanolamide, RVM = rostroventral medulla, PAG = periaqueductal gray, DR = dorsal raphe nucleus.Molecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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Endocannabinoid metabolism
To date, hydrolase and oxygenase pathways have been
shown to be the major pathways responsible for the
metabolism of the endocannabinoids, in particular AEA
and 2-AG (Figure 2). Hydrolysing enzymes include fatty
acid amide hydrolase (FAAH), monoacylglycerol lipase
(MAGL) and N-acylethanolamine-hydrolysing acid ami-
dase (NAAA). AEA and other NAEs are mainly hydrolysed
by FAAH through the hydrolytic cleavage of the amide
bond to form arachidonic acid and ethanolamine [101-
103]. An additional isoform of FAAH (FAAH2), has been
identified which has a limited species distribution in
mammals, being found in man and other primates, but
not in rodents [104]. FAAH2 appears to be poorly
expressed, if at all, in the brain. 2-AG is mainly metabo-
lised by MAGL to arachidonic acid and glycerol [105,106].
NAAA is a lysosomal enzyme with optimum activity at an
acid pH. It can metabolise AEA and PEA to their corre-
sponding fatty acids and ethanolamine, but 2-AG is a
poor substrate [107]. Levels of NAAA are low in the brain
and the enzyme is unlikely to be an important mediator
of endocannabinoid metabolism under normal condi-
tions.
AEA and 2-AG are also substrates for the oxidative
enzymes cyclooxygenase type-2 [COX-2; for review see;
[108]], lipooxygenase (LOX) and cytochrome p450s
(CYP450s). Whilst the effects of COX, LOX and CYP450
are not specific to endocannabinoid catabolism, their
effects on endocannabinoids are of interest, not least
because of the potential for oxidation of the arachidonic
acid moiety to generate pharmacologically active metabo-
lites. The proposed biological actions of some of these
metabolites are summarised in Table 2. COX-2 is consti-
tutively expressed in the kidney, spinal cord, hippocam-
pus, cortex and hypothalamus [102] and it is up-regulated
in pathological states, including inflammatory pain [109].
AEA and 2-AG can be converted by COX-2 to prostamides
(prostaglandin-ethanolamides) and prostaglandin glyc-
eryl esters, respectively [[110], for reviews see; [111,112]].
The prostamides are weakly active at cannabinoid CB1 and
CB2 receptors and prostamide F2α is a weak agonist at
TRPV1 [108,113]. Prostamides D2 and E2 are present in
mouse lung and kidney, with higher levels seen in AEA-
treated FAAH knockout mice, compared to control mice.
Prostamide F2α was only detected in the liver, kidney, lung
and small intestine of AEA-treated FAAH knockout mice.
[114].
Biological effects of the COX2 metabolite of 2-AG, pros-
taglandin glyceryl esters (PG-Gs) have been demonstrated
in the hippocampus, where they modulate GABAergic
mediated inhibitory synaptic transmission [115] and
enhance hippocampal glutamatergic transmission and
neurotoxocity [116]. 2-AG suppresses the elevation of
COX2 in response to pro-inflammatory stimuli, thus lim-
iting the generation of neurotoxic products of 2-AG [116].
The potential roles of COX2 metabolites of 2-AG in pain
processing have not been widely studied. Intraplantar
injection of PGE2-glyceryl ester (PGE2-G) produced
mechanical allodynia and thermal hyperalgesia, suggest-
ing that pro-nociceptive ligands could be generated by the
COX2 metabolism of 2-AG in vivo [117]. PGE2-G is
present in the rat hindpaw, but it was below detection
limits in the spinal cord and brain in naïve rats and
endogenous levels in the hindpaw were unaltered in a
model of inflammatory pain [117]. Further studies are
required to determine whether PGE2-G modulates spinal
and/or supraspinal nociceptive processing in models of
chronic pain.
The endocannabinoids are also metabolised by LOX and
CYP450s. The main isoforms of LOX that metabolise AEA
and 2-AG are 5-LOX, 12-LOX and 15-LOX, all of which
give rise to different subsets of metabolites. CYP450
enzymes 2D6, 3A4 and 4F2 produce several metabolites
of NAEs including 5,6-epoxyeicosatrienoic acid ethanola-
mide (5,6-EET-EA), which is more stable than AEA in
brain homogenate and is a potent and selective CB2 ago-
nist in vitro [118]. It is of particular interest, in the context
of chronic pain states, that activated BV-2 microglial cells
have an increased capacity to convert AEA to 5,6-EET-EA,
which may have relevance to neuropathic pain states.
Proposed metabolic pathways for the breakdown of AEA and  2-AG via hydrolase and oxygenase pathways Figure 2
Proposed metabolic pathways for the breakdown of 
AEA and 2-AG via hydrolase and oxygenase path-
ways.Molecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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Indeed, neuropathic pain states are, as discussed earlier,
associated with activated microglia, increased levels of
AEA in the spinal cord and the novel functional expres-
sion of CB2 receptors, activation of which attenuates noci-
ceptive responses. The role of metabolites such as 5,6-EET-
EA in the modulation of central sensitization in models of
chronic pain is unknown, and warrants investigation.
A novel group of CYP450 metabolites of AA has been
identified in the spleen, kidney and brain and were
termed 2-epoxyeicosatrienoyl-glycerols (2-EGs). Some of
these products, 2-(11,2-epoxyeicosatrienoyl)glycerol (2-
11,12-EG) and 2-(14,15- epoxyeicosatrienoyl)glycerol (2-
14,15-EG) have high affinity for CB1 and CB2 receptors in
transfected CHO cells [119]. 2-EG is present in the brain
and systemic administration of 2-EG decreased spontane-
ous locomotor activity and core body temperature in
mice, an effect which was sensitive to CB1, but not CB2
receptor, blockade. [119]. Whether 2-EG also produces
CB1  receptor-mediated analgesia remains to be deter-
mined.
As well as activating cannabinoid receptors, oxidative
metabolites of endocannabinoids also activate the PPAR
nuclear receptor family. The anti-inflammatory and anal-
gesic effects of PPARα ligands are discussed below. Both
the predominant product formed following incubation of
2-AG with 15-LOX, 15-HPETE-G, and the CYP450 metab-
olite of arachidonic acid, 8(S)-HETE, [120] are agonists at
the PPARα [102]. In addition, 2-(14,15)-DHETE-G, a
CYP450 metabolite of 2-AG, produces a four-fold increase
in PPAR-α activation in transfected COS-7 cells, suggest-
ing it is also a PPAR-α agonist [121]. It should be kept in
mind that there are many biological activators of PPARs
and, therefore, it is important to determine that potential
agonists can reach intracellular concentrations able to
activate these receptors before they are considered to be
functionally relevant.
Thus, is is evident that in addition to the more conven-
tional components of the endocannabinoid system, the
metabolism of endocannabinoids via the hydrolase and
oxidative pathways has the potential to generate various
modulators of physiological/pathophysiological process-
ing (Table 2), the generation of which is dependent on the
cell types present, their state of activation and the enzymes
expressed by these cells (Figure 3). In some cases ligands
which act via alternative receptor mechanisms are gener-
ated from the endocannabinoids, in other cases more sta-
ble ligands for the cannabinoid receptors are generated.
Further investigation of the biological significance of
these complex metabolic pathways in models of chronic
pain states are required to determine whether there are
important additional novel analgesic targets that can be
exploited.
Attenuation of endocannabinoid catabolism 
produces analgesia
Following the extensive study of the analgesic effects of
CB1 receptor activation in models of acute and chronic
Table 2: Summary of known biological actions of the endocannabinoid metabolites, and their effects in models of pain.
Synonym CB1 CB2 TRPV1 PPAR-α Effects in pain models Reference
PGD2-EA weak agonist weak agonist yet to be shown [108,113]
PGE2-EA weak agonist yet to be shown [108,113]
PGF2α-EA agonist weak agonist pro-inflammatory, produces allodynia [108,113,140,141]
PGE2-G pro-inflammatory, produces mechanical 
allodynia and thermal hyperalgesia
[108,113,117]
5,6-EET-EA agonist yet to be shown [118]
15-HPETE-G agonist yet to be shown [102]
2-(11,12)EG agonist agonist yet to be shown [119]
2-(14,15)EG agonist agonist yet to be shown [119]
2-(14,15)DHETE-G agonist yet to be shown [121]
PGD2-EA = prostamide D2, PGE2-EA = prostamide E2, PGF2α-EA = prostamide F2α, PGE2-G = prostaglandin E2-glyceryl ester, 5,6-EET-EA = 5,6-
epoxyeicosatrienoic acid ethanolamide, 15-HPETE-G = 15-hydroperoxyeicosatetraenoic acid glycerol ester, 2-(11,12)EG = 2(11,12-
epoxyeicosatrienoyl)glycerol, 2-(14,15)EG = 2(14,15-epoxyeicosatrienoyl)glycerol, 2-(14,15)DHETE-G = 2-(14,15-dihydroxyeicosatetraenoic acid)-
glycerol ester.Molecular Pain 2009, 5:59 http://www.molecularpain.com/content/5/1/59
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pain it was clear that a more selective approach was
required to achieve analgesia in the absence of the side-
effects produced by global stimulation of cannabinoid
receptors. The obvious strategy of preserving endocannab-
inoids by means of catabolic enzyme inhibition has been
employed by a number of research groups. This has the
potential to activate simultaneously a variety of relevant
targets by a whole range of different endocannabinoids
and related compounds that are substrates for the enzyme
in question. This has the advantage of promoting endo-
cannabinoid signalling predominantly at those sites at
which the neuronal activity is greatest, thereby selectively
controlling pain pathways when noxious stimuli are
present.
The role of FAAH in the metabolism of endocannabinoids
has been demonstrated in mice lacking FAAH (FAAH-/-),
which exhibit 15 fold elevated levels of AEA, compared to
wild-type mice. FAAH-/-  mice display phenotypic
hypoalgesia in models of acute and inflammatory pain
[122,123], but not neuropathic pain [123]. Pharmacolog-
ical inhibition of FAAH is antinociceptive in models of
acute and inflammatory pain [124-129]. A single systemic
injection of the FAAH inhibitor URB597 significantly
reduced thermal allodynia and mechanical hyperalgesia
in the complete Freund's adjuvant (CFA) model of
inflammation [124]. In the carrageenan model of inflam-
mation, we reported that intraplantar injection of
URB597 increased levels of AEA and 2AG in hindpaw skin
and reduced carrageenan-hyperalgesia [26]. Whilst the
analgesic effects of these compounds have been clearly
demonstrated, the selectivity and efficacy of URB597 has
recently been questioned. URB597 is an irreversible FAAH
inhibitor which also displays inhibitory activity at multi-
ple additional members of the serine hydrolase family
[130]. Reversible inhibitors such as OL-135 display
greater selectivity for FAAH, but have reduced efficacy
[126]. In light of this, novel FAAH inhibitors such as
JNJ1661010 [131] and PF-3845 [132] which have
enhanced selectivity and potency have been developed.
Both display robust anti-hyperalgesic properties in rat
models of inflammatory pain, which are sensitive to
blockade of CB1  and CB2  receptors by SR141716 or
SR144528 respectively [131,132].
The effects of inhibition of FAAH on neuropathic pain
behaviour are less consistent than those reported for
inflammatory pain states. Acute systemic injection of
URB597 (0.3 mg/kg, i.p.) did not alter mechanical allody-
nia in a model of peripheral neuropathy [124]. Similarly,
a single oral dose of URB597 (10 mg/kg, p.o.) had limited
effects on mechanical hyperalgesia in the chronic constric-
tion injury (CCI) model of peripheral neuropathy [129].
By contrast, repeated administration of URB597 (10 mg/
kg, for 4 days p.o.) significantly reduced thermal and
mechanical hyperalgesia [129] whilst OL135 (ED50 9
mg/kg i.p.) reduced mechanical allodynia [125] in neuro-
pathic rodents. Inhibition of FAAH by either URB597 or
OL135 also reduced mechanical and cold allodynia in
CCI mice. These inhibitory effects were blocked by CB1
but not CB2 or TRPV1 antagonists and were accompanied
by raised levels of AEA in the brain and spinal cord [133].
In addition to these studies, repeated subcutaneous
administration of URB597, OL-135 (3 mg/kg, 7 days), or
A: The endocannabinoid AEA and related NAEs PEA and  OEA are broken down by FAAH, 2-AG is primarily metabo- lized by MAGL Figure 3
A: The endocannabinoid AEA and related NAEs PEA 
and OEA are broken down by FAAH, 2-AG is prima-
rily metabolized by MAGL. AEA is a ligand at CB1, CB2 
and TRPV1 receptors and the nuclear receptor PPAR-α. 
OEA and PEA are ligands for PPAR-α. 2-AG is a ligand at 
CB1and CB2. Both AEA and 2-AG can be metabolized by 
COX2, LOX and CYP450 to form biologically active metabo-
lites, some of which are ligands for CB1, CB2 and PPAR-α. B: 
Under pathological conditions, such as inflammatory or neu-
ropathic pain, the presence of infiltrating immune cells or the 
activation of microglia provides another source of endocan-
nabinoid synthesis and catabolism, as well as providing addi-
tional/or alternative receptor sites of action of the 
endocannabinoids, NAEs and their metabolites.
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AA-5-HT (5 mg/kg, 7 days) from post-operative day 1
ablated the development of mechanical allodynia and
thermal hyperalgesia in the rat CCI model of neuropathic
pain [91]. Collectively, these data suggest that there is an
alteration in synthesis/metabolism of endocannabinoids
and endocannabinoid-like compounds, or their receptor
function, in models of neuropathic pain, which is sup-
ported by data from our electrophysiological studies
[134].
The focus of research in this area has centred on the pre-
vention of AEA catabolism by FAAH, largely due to the
paucity of selective inhibitors for the major 2-AG cata-
bolic enzyme; MAGL [79,102,135]. Recently a novel com-
pound, JZL184, which has >300 fold selectivity for MAGL
over FAAH in vitro, has been described [135]. JZL184 sig-
nificantly increases levels of 2-AG in vivo and produces
analgesia in mouse models of acute and inflammatory
pain [136]. JZL184 also attenuated mechanical and cold
allodynia in CCI mice, effects which were mediated by the
CB1 receptor and were accompanied by raised levels of 2-
AG in the brain and spinal cord [133]. Further use of this
and other recently described compounds (e.g. OMDM169
[137]) alone and in conjunction with existing inhibitors
will provide greater insight into the respective roles of 2-
AG and AEA in pain states, and aid the future develop-
ment of analgesics based on attenuation of EC catabo-
lism.
Role of PPARs in mediating analgesic effects of 
FAAH inhibition
There is increasing evidence that, in addition to cannabi-
noid receptor mediated analgesia, NAEs such as PEA pro-
duce analgesia via activation of nuclear receptors (Figure
3). PEA is an endogenous ligand of PPAR-α and periph-
eral administration of PEA rapidly reduces formalin-
evoked nocifensive behaviours and neuronal activity in
mice [77]. The role of the PPAR-α in the analgesic effects
of PEA was confirmed by the absence of these effects in
PPAR-α null mice. Although PPAR-α is a nuclear receptor,
the rapid onset of these effects suggests that mechanisms
independent of gene transcription, which may include
central sites of action, may contribute to these effects,
[138]. In addition to its effects at PPAR-α, anti-allodynic
and antihyperalgesic effects of PEA are mediated, at least
in part, by PPAR-gamma [19]. We have demonstrated that
the inhibition of inflammatory pain behaviour associated
with the increase in levels of AEA and NAEs, produced by
inhibition of FAAH and COX-2, is mediated at least in
part through activation of PPAR-α [26]. Electrophysiolog-
ical studies in our group have confirmed the role of PPAR-
α in mediating the effects of URB597 on carrageenan-
evoked receptive field expansion [27]. Although further
studies are required, it is likely that the contribution of
PPAR-α in mediating the effects of FAAH and COX2 inhi-
bition arises as a result of the presence of additional tar-
gets in inflammatory pain states, for example infiltrating
immune cells (Figure 3).
In conclusion, cannabinoid ligands produce well docu-
mented analgesic effects mediated by the CB1 and CB2
receptors; however, other receptor systems may also con-
tribute, in particular in inflammatory and neuropathic
pain states (Figure 3). The emerging evidence that the lev-
els of cannabinoid receptors, their ligands and biologi-
cally active metabolites are altered in a tissue-specific
manner under pathological conditions, such as chronic
pain states, may support a more targeted approach to the
development of cannabinoid-based analgesics.
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